Zhenping Zhu

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA.

Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA.

The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Hong Kong Institute of Certified Public Accountants operates under the professional accountant’s ordinance and works in the public interest. It offers CPA qualification programme and promulgating financial reporting, auditing and ethical standards in Hong Kong. The company was founded on January 1, 1973 and is headquartered in Hong Kong.

International Financial Management Association (Hong Kong) offers a variety of real-life examples, both numerical and institutional, that demonstrate the use of financial analysis and reasoning in solving international financial problems. The company is headquartered in Hong Kong.

Garden Fresh Group Holding Co., Ltd. offers green food and beverages. It researches, develops, produces, and sells loquat juice drinks through its subsidiary. The company was founded by Huang Yu Feng on March 6, 2014 and is headquartered in Shenzhen, China.

Sichuan Baicha Baidao Industrial Co., Ltd. operates as an investment holding company. It focuses on royalty and franchising services to franchisees. The Company was founded by Xiao Kun Wang and Wei Hong Liu on December 31, 2020 and is headquartered in Sichuan, China.

F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.

F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA.

Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA.

Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA.

Part of Carrick Therapeutics Ltd., Carrick Therapeutics UK Ltd. is a clinical-stage biopharmaceutical company based in Oxford, UK. Carrick Therapeutics translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, working in combination with existing oncology drugs to address unmet patient needs. The British company focuses on developing innovative therapies to improve patient outcomes in oncological therapy. The company's therapies have potential in advanced breast, prostate, and ovarian cancers, with further potential in pancreatic and Ewing's sarcoma. Timothy R. Pearson has been the CEO of the company since 2019.